86 related articles for article (PubMed ID: 9004975)
1. [Estradiol valerate/cyproterone acetate in the treatment of climacteric syndrome].
Zivný J; Skrenková J
Ceska Gynekol; 1996 Oct; 61(5):294-6. PubMed ID: 9004975
[TBL] [Abstract][Full Text] [Related]
2. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
Tuppurainen M; Heikkinen AM; Penttilä I; Saarikoski S
Maturitas; 1995 Jun; 22(1):55-61. PubMed ID: 7666817
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experiences with Climen in peri- and postmenopausal women].
Husmann F
Zentralbl Gynakol; 1997; 119(3):123-7. PubMed ID: 9173770
[TBL] [Abstract][Full Text] [Related]
4. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
Schram JH; Boerrigter PJ; The TY
Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
[TBL] [Abstract][Full Text] [Related]
5. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate).
Alwers R; Urdinola J; Onatra W; Sánchez F; Posso H
Maturitas; 1999 May; 32(1):41-50. PubMed ID: 10423715
[TBL] [Abstract][Full Text] [Related]
6. Endocrine effects in Asian postmenopausal women treated with SH D 461 M and Prempak-C.
Goh HH; McCarthy TG; Dramusic V; Costales A; Junge W; Ratnam SS
Maturitas; 1994 Dec; 20(2-3):165-73. PubMed ID: 7715469
[TBL] [Abstract][Full Text] [Related]
7. Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women.
Georgiev DB; Golbs S; Goudev A
Methods Find Exp Clin Pharmacol; 2001 May; 23(4):197-202. PubMed ID: 11676228
[TBL] [Abstract][Full Text] [Related]
8. Effect of different hormone replacement therapy regimens on circadian blood pressure profile and active renin in postmenopausal women.
Zacharieva S; Kirilov G; Kalinov K; Shigarminova R; Nachev E; Orbetzova M; Atanassova I
Gynecol Endocrinol; 2002 Dec; 16(6):461-7. PubMed ID: 12626033
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effect of two hormonal preparations in postmenopausal women.
Bissonnette F; Lussier-Cacan S; Fugère P; Bérubé S
Maturitas; 1997 Jul; 27(3):275-84. PubMed ID: 9288700
[TBL] [Abstract][Full Text] [Related]
10. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Marslew U; Overgaard K; Riis BJ; Christiansen C
Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome.
Gambacciani M; Spinetti A; Orlandi R; Piaggesi L; Cappagli B; Weiss C; Ciaponi M; Genazzani AR
Maturitas; 1995 Sep; 22(2):115-20. PubMed ID: 8538479
[TBL] [Abstract][Full Text] [Related]
12. Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause.
Polatti F; Capuzzo E; Viazzo F; Colleoni R; Abbiati I; Nappi RE
Acta Obstet Gynecol Scand; 1999 Jan; 78(1):49-53. PubMed ID: 9926892
[TBL] [Abstract][Full Text] [Related]
13. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation.
Koninckx PR; Lauweryns JM; Cornillie FJ
Maturitas; 1993 Mar; 16(2):97-110. PubMed ID: 8387151
[TBL] [Abstract][Full Text] [Related]
14. Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT).
McCarthy T; Dramusic V; Carter R; Costales A; Ratnam SS
Maturitas; 1995 Jun; 22(1):13-23. PubMed ID: 7666812
[TBL] [Abstract][Full Text] [Related]
15. Endocrine effects in Asian postmenopausal women, treated with SH D 461 M and Prempak-C.
Goh HH; McCarthy TG; Dramusic V; Costales A; Junge W; Ratnam SS
Maturitas; 1995 Jan; 21(1):17-25. PubMed ID: 7731378
[TBL] [Abstract][Full Text] [Related]
16. [Effect of estradiol valerate and chlormadinone acetate in hormone replacement therapy in postmenopause on Kupperman index, body weight, blood pressure, lipids, enzymes and electrolytes].
Göretzlehner G; Nikschick S; Zimmermann T
Zentralbl Gynakol; 1996; 118(7):420-5. PubMed ID: 8766107
[TBL] [Abstract][Full Text] [Related]
17. The role of antiandrogens in hormone replacement therapy.
Schneider HP
Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
[TBL] [Abstract][Full Text] [Related]
18. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
Grisar J; Travica S; Metka M; Pietschmann P
Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
[TBL] [Abstract][Full Text] [Related]
19. [Effects of a sequential combination of estradiol valerate and cyproterone acetate on the functional properties of the arterial wall in menopausal women].
Mares P; Dauzat M; Abramovici Y; Deklunder G; Body G; Crepin G; Denis A; Favier M
Gynecol Obstet Fertil; 2000; 28(7-8):509-17. PubMed ID: 10996962
[TBL] [Abstract][Full Text] [Related]
20. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease.
Vitale C; Fini M; Leonardo F; Rossini P; Cerquetani E; Onorati D; Rosano GM
Maturitas; 2001 Dec; 40(3):239-45. PubMed ID: 11731185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
